Modality
ERT
MOA
CAR-T BCMA
Target
PSMA
Pathway
Angiogenesis
LGS
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
~Dec 2017
→ ~Mar 2019
Phase 3
Jun 2019
→ Jan 2030
Phase 3Current
NCT07359607
1,716 pts·LGS
2025-11→2030-01·Active
NCT04813897
773 pts·LGS
2019-06→2029-08·Completed
NCT03074124
1,639 pts·LGS
2022-07→2027-09·Terminated
4,128 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-09-071.4y awayPh3 Readout· LGS
2029-08-193.4y awayPh3 Readout· LGS
2030-01-013.8y awayPh3 Readout· LGS
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P3
Complet…
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2027-09-07 · 1.4y away
LGS
Ph3 Readout
2029-08-19 · 3.4y away
LGS
Ph3 Readout
2030-01-01 · 3.8y away
LGS
ActiveCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07359607 | Phase 3 | LGS | Active | 1716 | MRD |
| NCT04813897 | Phase 3 | LGS | Completed | 773 | Mayo |
| NCT03074124 | Phase 3 | LGS | Terminated | 1639 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA |